Corcoran Nicholas 4
4 · TransMedics Group, Inc. · Filed Jul 14, 2026
Research Summary
AI-generated summary of this filing
TransMedics SVP Nicholas Corcoran Receives RSUs and Stock Option Award
What Happened Nicholas Corcoran, SVP of Supply Chain and Operations at TransMedics Group (TMDX), received equity compensation on July 10, 2026: 11,727 restricted stock units (RSUs) and a 17,784-share stock option award. Both grants were reported with an acquisition price of $0.00 (typical for awards), totaling 29,511 shares subject to future vesting and settlement.
Key Details
- Transaction date: July 10, 2026; Form 4 filed July 14, 2026 (filed on time).
- Grants: 11,727 RSUs (each RSU = contingent right to one share) and a 17,784-share option award (reported as a derivative).
- Vesting for the option: vests at 2.0833% of the option monthly beginning April 10, 2026 and fully vests April 10, 2030, subject to continued service (per footnote).
- Reported acquisition price: $0.00 for both awards (compensation grants, not market purchases).
- Shares owned after transaction: not specified in the provided filing.
Context These are compensation awards, not open-market purchases or sales. RSUs convert to common stock upon vesting; the option vests over ~4 years monthly, subject to continued employment. Such grants are routine executive compensation disclosures and do not by themselves indicate an immediate buy or sell decision.
Insider Transaction Report
- Award
Common Stock
[F1]2026-07-10+11,727→ 41,558 total - Award
Stock Option (Right to Buy)
[F2]2026-07-10+17,784→ 17,784 totalExercise: $71.23Exp: 2036-07-10→ Common Stock (17,784 underlying)
Footnotes (2)
- [F1]Consists of 11,727 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The option vests at a rate of 2.0833% of the total number of shares subject to the option each month following April 10, 2026 until the option is fully vested on April 10, 2030, subject to continued service.